Youhua Zhang1, Eduard I Dedkov2, Bianca Lee2, Ying Li2, Khusbu Pun2, A Martin Gerdes2. 1. Department of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York. Electronic address: yzhang49@nyit.edu. 2. Department of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
Abstract
BACKGROUND: Heart failure (HF) is associated with increased atrial fibrillation (AF) risk. Accumulating evidence suggests the presence of myocardial tissue hypothyroidism in HF, which may contribute to HF development. In a recent report we demonstrated that hypothyroidism, like hyperthyroidism, leads to increased AF inducibility. The present study was designed to investigate the effect of thyroid hormone (TH) replacement therapy on AF arrhythmogenesis in HF. METHODS AND RESULTS: Myocardial infarction (MI) was produced in rats by means of coronary artery ligation. Rats with large MIs (>40%) were randomized into L-thyroxine (T4; n = 14) and placebo (n = 15) groups 2 weeks after MI. Rats received 3.3 mg T4 (in 60-day release form) or placebo pellets for 2 months. Compared with the placebo, T4 treatment improved cardiac function and decreased left ventricular internal diameters as well as left atrial diameter. T4 treatment attenuated atrial effective refractory period prolongation (45 ± 1.5 ms in placebo group vs 37 ± 1.6 ms in T4 group; P < .01) and reduced AF inducibility (AF/atrial flutter/tachycardia were inducible in 11/15 rats [73%] in the placebo- vs 4/14 rats [29%] in the T4-treated group; P < .05). Arrhythmia reduction was associated with decreased atrial fibrosis but was not associated with connexin 43 changes. CONCLUSIONS: To our knowledge this is the first study demonstrating that TH replacement therapy in HF attenuates atrial remodeling and reduces AF inducibility after MI-HF. Clinical studies are needed to confirm such benefits in human patients.
BACKGROUND:Heart failure (HF) is associated with increased atrial fibrillation (AF) risk. Accumulating evidence suggests the presence of myocardial tissue hypothyroidism in HF, which may contribute to HF development. In a recent report we demonstrated that hypothyroidism, like hyperthyroidism, leads to increased AF inducibility. The present study was designed to investigate the effect of thyroid hormone (TH) replacement therapy on AF arrhythmogenesis in HF. METHODS AND RESULTS:Myocardial infarction (MI) was produced in rats by means of coronary artery ligation. Rats with large MIs (>40%) were randomized into L-thyroxine (T4; n = 14) and placebo (n = 15) groups 2 weeks after MI. Rats received 3.3 mg T4 (in 60-day release form) or placebo pellets for 2 months. Compared with the placebo, T4 treatment improved cardiac function and decreased left ventricular internal diameters as well as left atrial diameter. T4 treatment attenuated atrial effective refractory period prolongation (45 ± 1.5 ms in placebo group vs 37 ± 1.6 ms in T4 group; P < .01) and reduced AF inducibility (AF/atrial flutter/tachycardia were inducible in 11/15 rats [73%] in the placebo- vs 4/14 rats [29%] in the T4-treated group; P < .05). Arrhythmia reduction was associated with decreased atrial fibrosis but was not associated with connexin 43 changes. CONCLUSIONS: To our knowledge this is the first study demonstrating that TH replacement therapy in HF attenuates atrial remodeling and reduces AF inducibility after MI-HF. Clinical studies are needed to confirm such benefits in humanpatients.
Authors: Yi-Da Tang; James A Kuzman; Suleman Said; Brent E Anderson; Xuejun Wang; A Martin Gerdes Journal: Circulation Date: 2005-11-07 Impact factor: 29.690
Authors: Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong Journal: Circulation Date: 2009-01-27 Impact factor: 29.690
Authors: Steven Goldman; Madeline McCarren; Eugene Morkin; Paul W Ladenson; Robert Edson; Stuart Warren; Janet Ohm; Hoang Thai; Lori Churby; Jamie Barnhill; Terrence O'Brien; Inder Anand; Alberta Warner; Brack Hattler; Mark Dunlap; John Erikson; Mei-Chiung Shih; Phil Lavori Journal: Circulation Date: 2009-06-08 Impact factor: 29.690
Authors: Kyle K Henderson; Sara Danzi; Jennifer T Paul; Greg Leya; Irwin Klein; Allen M Samarel Journal: Circ Heart Fail Date: 2009-03-25 Impact factor: 8.790
Authors: Ki-Hun Kim; Sanghamitra Mohanty; Prasant Mohanty; Chintan Trivedi; Eli Hamilton Morris; Pasquale Santangeli; Rong Bai; Amin Al-Ahmad; John David Burkhardt; Joseph G Gallinghouse; Rodney Horton; Javier E Sanchez; Shane Bailey; Patrick M Hranitzky; Jason Zagrodzky; Soo G Kim; Luigi Di Biase; Andrea Natale Journal: J Interv Card Electrophysiol Date: 2017-03-07 Impact factor: 1.900
Authors: Kristine M Wadosky; Jessica M Berthiaume; Wei Tang; Makhosi Zungu; Michael A Portman; A Martin Gerdes; Monte S Willis Journal: J Mol Endocrinol Date: 2016-02-09 Impact factor: 5.098